To this end, Tenthoff still expects total Mycapssa sales to clock in at $3 million in Q4 2020.Tenthoff also points out that with the first commercial sale of Mycapssa, CHMA is set to receive $15 million from Healthcare Royalty Partners (HCR) and $10 million in early 2022. Acromegaly is an orphan disease typically caused by a benign tumor on the pituitary that results in the excessive secretion of growth hormones, causing bone overgrowth and enlargement of internal organs with co-morbidities.In terms of pricing, a 28-day supply goes for $5,152, with CHMA intending to build on physician and patient experience with octreotide, incorporate telemedicine and build a sales team of 45 representatives.Weighing in on this development for Piper Sandler, 5-star analyst Edward Tenthoff tells clients he is optimistic about the therapy’s prospects. (To watch Furlong’s track record, click here)In general, other analysts are on the same page. I don’t mean to brag, but yours truly. Catch financial instability early by keeping an eye out for these red flags from your partner. Fang said that the amount is 77% higher than the estimated cash flow. Source: Sundry Photography /, 10 predictions for the stock market in 2019, Growth to Go with 2 Cheap Classic Tech Stocks, The Overlooked Significance of Tesla’s Battery Day, Trump vs. Biden: Stocks to Buy No Matter Who Wins the White House, SPI Stock News: Why SPI Energy Is Surging 700% Today, 7 5G Stocks for the Next Communication Revolution, 10 Stocks For Beginners To Buy Today For Profits Tomorrow, The Holes in the Bull Case for Workhorse Stock, Buy Exxon Mobil Stock While It’s Still Deeply Unpopular. Putting all that together, I think NIO stock has a reasonably good chance to more than triple in 2020. As of this writing, Matt did not hold a position in any of the aforementioned securities. )For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P. For those that thought the extreme market volatility was behind us, think again. Why It Might Not Happen: The 2020 pot stock rebound thesis is entirely predicated on three things: revenue trend improvements, margin trend improvements and U.S. legislation progress. Of note, I particularly like Beyond Meat and Pinterest as potentially 100%-plus upside candidates for 2020. Therefore, long-term investors shouldn’t get discouraged by Goldman Sachs’s downgrade. If that does happen, neither of these stocks will rebound. Shares of Chinese electric vehicle maker NIO  (NIO) - Get Report were down slightly Wednesday despite analysts at Piper Sandler and JPMorgan increasing their firm's price targets following Nio's healthy second-quarter earnings report. Despite the dip, one can argue that bulls are still in control. Only Buy ratings, 4, in fact, have been issued in the last three months. The company continues to churn out vehicles and hit its delivery marks. “We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing,” the analyst added.If that wasn’t enough, PROG signed its first GI Precision Medicine partnership agreement with a top-20 Pharma company in August. (To watch Schwartz’s track record, click here)What does the rest of the Street have to say? NIO Inc. (NYSE: NIO) extends the consolidation around $14.00. Second, China’s economy will rebound in 2020 after slowing for most of 2018 and 2019, thanks to easing U.S.-China trade tensions. Mah commented, “We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.”To sum it all up, Mah said, “We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.”To this end, Mah rates PROG an Overweight (i.e. “This will require discipline from the company, ensuring a delicate balance between working toward decarbonization targets while achieving attractive returns for shareholders.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P. Legal questions now loom after electric truck entrepreneur, Trevor Milton, stepped down Monday as executive chairman and board member of his newly public company Nikola. recent capital infusion makes for an atypical ownership structure -- but cash is cash, and He owes his trading success to these strategies. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.”Additionally, health insurer Aetna is temporarily extending coverage of average-risk NIPT until year-end as a result of the pandemic, with the American College of Obstetricians and Gynecologists (ACOG) also expected to endorse average-risk in the future given its clinical utility, in Mah’s opinion.Reflecting another positive, the fourth generation NIPT (single-molecule counting assay) test was able to measure fetal fraction, a key milestone according to Mah, and will continue to be developed into 2021.